logo
Plus   Neg
Share
Email

AstraZeneca : Phase II DESTINY-CRC01 Trial Shows Clinically Meaningful Activity In Colorectal Cancer

AstraZeneca and Daiichi Sankyo Company said that Results from the ongoing Phase II DESTINY-CRC01 trial showed the companies's ENHERTU demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.

Colorectal cancer is the third most common cancer and second most common cause of cancer death globally.

The primary endpoint of confirmed objective response rate (ORR), assessed by independent central review, showed 45.3% of patients with HER2-positive (defined as IHC3+ or IHC2+/ISH+) advanced colorectal cancer treated with ENHERTU monotherapy (6.4mg/kg) achieved a tumor response.

A disease control rate (DCR) of 83.0% was observed with a median progression-free survival (PFS) of 6.9 months. Median duration of response and overall survival had not yet been reached at the time of data cut-off.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lord & Taylor joined the growing list of U.S. retailers who filed for bankruptcy amid the coronavirus pandemic. Lord & Taylor, one of the oldest department store chains in the U.S., filed for bankruptcy protection in the Eastern Court of Virginia on Sunday. The company operated 38 stores that have remained temporarily closed since March this year due to the pandemic. Thomson International Inc. is recalling Red, Yellow, White, and Sweet Yellow Onions for potential contamination with Salmonella, according to a statement by the U.S. Food and Drug Administration or FDA. The onions are in distribution since May 1, 2020. They were sold to wholesalers, restaurants, and retail stores in all 50 U.S. states, the District of Columbia and Canada. Tyson Foods, Inc. (TSN) reported third quarter adjusted net income per share attributable to company of $1.40 compared to $1.47, a year ago. On average, 12 analysts polled by Thomson Reuters expected the company to report profit per share of $0.94, for the quarter. Analysts' estimates typically exclude...
Follow RTT